Share This Article:

UGT1A1*28 Polymorphism in Advanced Colorectal Cancer: The Story Is Not Yet Ended

Abstract Full-Text HTML Download Download as PDF (Size:257KB) PP. 53-59
DOI: 10.4236/jct.2014.51007    3,660 Downloads   5,239 Views  


Background: UGT1A1*28 polymorphism is associated with neutropenia and diarrhea in previous reports, while this study tried to investigate correlation with other toxicities like vomiting. Patients and Methods: This is a prospective case control study including all eligible cases of advanced colorectal cancer. The genotypes of UGT1A1*28 was assessed in the peripheral blood and/or in tissues by PCR. Patients were divided into two groups, Group 1: patients with no mutation, Group 2: patients with homo or hetero mutation. All patients received standard IFL regimen. Primary objectives were: 1) comparison between the 2 groups as regard vomiting, 2) assessment of the incidence of UGT1A1*28 polymorphism. Secondary objectives were: comparison between the 2 groups as regard: neutropenia, diarrhea, treatment delay, progressive diseases (PD), progression free survival (PFS) and overall survival (OS). Results: 46 cases of advanced colorectal cancer present to National Cancer Institute, Cairo University, aged between 19 and 71 years with a median age of 45 years were included and followed up during the period from September 2010 to January 2013 with a median follow-up of 9 months. UGT1A1*28 polymorphism was present in 20 patients (43%), of whom 15% are homozygous. Grade (II-IV) vomiting was found in 8.3% of Group 1 versus 52.5% of Group 2 (P = 0.01). Grade (II-IV) neutropenia was found in 20.8% of Group 1 versus 64.7% of Group 2 (P = 0.03). Grade (II-IV) diarrhea was found in 37.5% of patients of Group 1 and 27.5% of patients with Group 2. (P = 0.75). Treatment delay occurred in 29.16% of Group 1 versus 72.4% of Group 2 (P = 0.02). 25% of Group 1 showed PD versus 25% of Group 2 (P = 0.8). 1-year PFS was 19% in Group 1 versus 23% in Group 2 (P = 0.8) while there was a trend towards better OS in Group 1 (47% versus 35%) (P = 0.07). Conclusions: UGT1A1*28 polymorphism is present frequently (43%) in a Caucasian population and is associated with more vomiting, neutropenia and treatment delay.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

A. Bastawisy, A. Bahnasy, A. El-Zeiny and S. Farid, "UGT1A1*28 Polymorphism in Advanced Colorectal Cancer: The Story Is Not Yet Ended," Journal of Cancer Therapy, Vol. 5 No. 1, 2014, pp. 53-59. doi: 10.4236/jct.2014.51007.


[1] R. Siegel, D. Naishadham and A. Jemal, “Cancer Statistics,” CA: A Cancer Journal for Clinicians, Vol. 62, No. 1, 2012, pp. 10-29.
[2] G. G. Chabot, “Clinical Pharmacokinetics of Irinotecan,” Clinical Pharmacokinetics, Vol. 33, No. 4, 1997, pp. 245-259.
[3] J.-F. Cote, S. Kirzin, A. Kramar, J.-F. Mosnier, M.-D. Diebold, I. Soubeyran, A.-S. Thirouard, J. Selves, P. Laurent-Puig and M. Ychou, “UGT1A1 Polymorphism Can Predict Hematologic Toxicity,” Clinical Cancer Research, Vol. 13, 2007, p. 3269.
[4] L. Iyer, S. Das, L. Janisch, M. Wen, J. Rami’rez, T. Karrison, G. F. Fleming, E. E. Vokes, R. L. Schilsky and M. J. Ratain, “UGT1A1 Genotype and Irinotecan Disposition & Toxicity,” The Pharmacogenomics Journal, Vol. 2, 2002, pp. 43-47.
[5] L. Iyer, D. Hall, S. Das, M. A. Mortell, J. Ramirez, S. Kim, et al., “Phenotypegenotype Correlation of in Vitro SN-38 (Active Metabolite of Irinotecan) and Bilirubin Glucuronidation in Human Liver Tissue with UGT1A1 Promoter Polymorphism,” Clinical Pharmacology & Therapeutics, Vol. 65, 1999, pp. 576-582.
[6] F. Innocenti, C. Grimsley, S. Das, et al., “Haplotype Structure of the UDP-Glucuronosyltransferase 1A1 Promoter in Different Ethnic Groups,” Pharmacogenetics, Vol. 12, No. 9, 2002, pp. 725-733.
[7] H. Minami, K. Sai, M. Saeki, Y. Saito, S. Ozawa, K. Suzuki, N. Kaniwa, J. Sawada, T. Hamaguchi, N. Yamamoto, K. Shirao, Y. Yamada, H. Ohmatsu, K. Kubota, T. Yoshida, A. Ohtsu and N. Saijo, “Irinotecan Pharmacokinetics/Pharmacodynamics and UGT1A Genetic Polymorphisms in Japanese: Roles of UGT1A1*6 and *28,” Pharmacogenet Genomics, Vol. 17, No. 7, 2007, pp. 497-504.
[8] E. A. Eisenhauer, P. Therasse, B. Bogaerts, L. H. Schwartz, D. Sargent, R. Ford, et al., “New Response Evaluation Criteria in Solid Tumors: Revised RECIST Guideline (Version 1.1),” European Journal of Cancer, Vol. 45, No. 2, 2009, pp. 228-247.
[9] “Common Terminology Criteria for Adverse Events,” Version 4.0, DCTD, NCI, NIH, DHHS, 2009.
[10] L. Iyer1, S. Das, L. Janisch, M. Wen, J. Rami′rez, T. Karrison, G. F. Fleming, E. E. Vokes, R. L. Schilsky and M. J. Ratain, “UGT1A1*28 Polymorphism as a Determinant of Irinotecan Disposition and Toxicity,” The Pharmacogenomics Journal, Vol. 2, No. 1, 2002, pp. 43-47.
[11] Y. Akiyama, et al., “Genetic Testing for UGT1A1*28 and *6 in Japanese Patients Who Receive Irinotecan Chemotherapy,” Annals of Oncology, Vol. 19, No. 12, 2008, pp. 2089-2090.
[12] X. Q. Zhang, G. K. Ao, Y. W. Wang, W. Yan, M. Wang, E. F. Chen, F. F. Yang and J. Yang, “Genetic Variants and Haplotypes of the UGT1A9, 1A7 and 1A1 Genes in Chinese Han,” Genetics and Molecular Biology, Vol. 35, No. 2, 2012, pp. 428-434. 12005000036
[13] A. Zhang, Q. Xing, S. Qin, J. Du, L. Wang, L. Yu, X. Li, L. Xu, M. Xu, G. Feng, et al., “Intra-Ethnic Differences in Genetic Variants of the UGT-Glucuronosyltransferase 1A1 Gene in Chinese Populations,” Pharmacogenomics Journal, Vol. 7, No. 5, 2007, pp. 333-338. 1038/sj.tpj.6500424
[14] K. S. Tang, H. F. Chiu, H. H. Chen, H. L. Eng, C. J. Tsai, H. C. Teng and C. S. Huang, “Link between Colorectal Cancer and Polymorphisms in the Uridine-Diphosphoglucuronosyltransferase 1A7 and 1A1 Genes,” World Journal of Gastroenterology, Vol. 11, 2005, pp. 3250-3254.
[15] Y. Y. Zhou, L. Y. Lee, S. Y. Ng, C. P. P. Hia, K. T. Low, Y. S. Chong and D. L. M. Goh, “UGT1A1 Haplotype Mutation among Asians in Singapore,” Neonatology, Vol. 96, 2009, pp. 150-155.
[16] M. Saeki, Y. Saito, H. Jinno, K. Sai, S. Ozawa, K. Kurose, N. Kaniwa, K. Komamura, T. Kotake, H. Morishita, et al., “Haplotype Structures of the UGT1A Gene Complex in a Japanese Population,” Pharmacogenomics Journal, Vol. 6, 2006, pp. 63-75.
[17] S. S. Yea, S. S. Lee, W. Y. Kim, K. H. Liu, H. Kim, J. H. Shon, I. J. Cha and J. G. Shin, “Genetic Variations and Haplotypes of UDP-Glucuronosyltransferase 1A Locus in a Korean Population,” Therapeutic Drug Monitoring, Vol. 30, No. 1, 2008, pp. 23-34.
[18] S. S. Thomas, S. S. Li, J. W. Lampe, J. D. Potter and J. Bigler, “Genetic Variability, Haplotypes, and htSNPs for Exons 1 at the Human UGT1A Locus,” Human Mutation, Vol. 27, No. 7, 2006, p. e717.
[19] C. Schulz, V. Heinemann, A. Schalhorn, N. Moosmann, T. Zwingers, S. Boeck, C. Giessen and H.-J. Stemmler, “UGT1A1 Gene Polymorphism: Impact on Toxicity and Efficacy of Irinotecan-Based Regimens in Metastatic Colorectal Cancer,” World Journal of Gastroenterology, Vol. 15, No. 40, 2009, pp. 5058-5066.
[20] C.-Y. Liu, P.-M. Chen, T.-J. Chiou, J.-H. Liu, J. K. Lin, T.-C. Lin, W.-S. Chen, J.-K. Jiang, H.-S. Wang and W.-S. Wang, “UGT1A1*28 Polymorphism Predicts Irinotecan-Induced Severe Toxicities without Affecting Treatment Outcome and Survival in Patients with Metastatic Colorectal Carcinoma,” Cancer, Vol. 112, No. 9, 2008, pp. 1932-1940.
[21] K. K. Hahn, J. J. Wolff and J. M. Kolesar, “Pharmacogenetics and Irinotecan Therapy,” American Journal of Health-System Pharmacy, Vol. 63, No. 22, 2006, pp. 2211-2217. ajhp060155
[22] F. Innocenti, S. D. Undevia, L. Iyer, P. X. Chen, S. Das, M. Kocherginsky, T. Karrison, L. Janisch, J. Ramírez, C. M. Rudin, E. E. Vokes and M. J. Ratain, “Genetic Variants in the UDP-Glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan,” Journal of Clinical Oncology, Vol. 22, No. 8, 2004, pp. 1382-1388.
[23] E. Rouits, M. Boisdron-Celle, A. Dumont, O. Guérin, A. Morel and E. Gamelin, “Relevance of Different UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity: A Molecular and Clinical Study of 75 Patients,” Clinical Cancer Research, Vol. 10, No. 15, 2004, pp. 5151-5159.
[24] G. E. Palomaki, L. A. Bradley, M. P. Douglas, K. Kolor and W. D. Dotson, “Can UGT1A1 Genotyping Reduce Morbidity and Mortality in Patients with Metastatic Colorectal Cancer Treated with Irinotecan? An Evidence-Based Review,” Genetics in Medicine, Vol. 11, No. 1, 2009, pp. 21-34.
[25] E. Marcuello, A. Altes, A. Menoyo, E. Del Rio, M. Gómez-Pardo and M. Baiget, “UGT1A1 Gene Variations and Irinotecan Treatment in Patients with Metastatic Colorectal Cancer,” British Journal of Cancer, Vol. 91, No. 4, 2004, pp. 678-682.
[26] G. Toffoli, E. Cecchin, G. Corona, et al., “The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients with Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 24, No. 19, 2006, pp. 3061-3068. 1200/JCO.2005.05.5400

comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.